Scholar Rock Holding Corp (SRRK) · Insider trading
What Scholar Rock Holding's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$0
0 insiders, 0 trades
Sold, 12 months
$19.44M
13 insiders, 45% under a plan
Net, 12 months
−$19.44M
bought less sold
Latest filing
2026-09-25
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Debbane Raymond10% owner | – | $82.40M | 6 | 2024-12-10 | 9,250,005 |
| Akkaraju SrinivasDirector | $19.99M | – | 9 | 2025-10-07 | – |
| Qatanani MoCHIEF SCIENTIFIC OFFICER | – | $12.80M | 18 | 2026-02-23 | 99,502 |
| Myles Edward HCOO & CFO | – | $5.91M | 4 | 2025-03-10 | 140,740 |
| Hallal DavidDirector, Chief Executive Officer | – | $3.97M | 2 | 2026-04-16 | 1,639,034 |
| Flier Jeffrey S.Director | – | $1.82M | 9 | 2026-07-01 | 29,341 |
| Vaishnaw AkshayDirector, President of R&D | – | $1.68M | 4 | 2026-04-16 | 630,542 |
| Backstrom Jay T.Director, CHIEF EXECUTIVE OFFICER | – | $1.66M | 2 | 2025-02-18 | 311,991 |
| Ho JunlinGENERAL COUNSEL | – | $1.65M | 5 | 2026-02-17 | 241,545 |
| Parlavecchio CarynCHRO | – | $1.46M | 6 | 2026-02-17 | 169,087 |
| Sinha VikasChief Financial Officer | – | $1.23M | 2 | 2026-04-16 | 619,856 |
| Woods KeithChief Operating Officer | – | $1.22M | 2 | 2026-04-16 | 620,055 |
| Marantz Jing L.CHIEF MEDICAL OFFICER | – | $1.08M | 9 | 2026-02-17 | 126,012 |
| Sacco TraceyChief Commercial Officer | – | $551,045 | 5 | 2025-04-25 | 71,834 |
| Peng KatieDirector | – | $502,010 | 10 | 2026-07-01 | 36,759 |
| Moore ErinInterim PFO and PAO | – | $449,240 | 1 | 2025-03-24 | 82,609 |
| Burow KristinaDirector | – | $324,546 | 4 | 2026-07-01 | 115,605 |
| Reed JoshuaDirector | – | $324,527 | 4 | 2026-07-01 | 20,466 |
| Gilman MichaelDirector | – | $237,349 | 5 | 2026-07-01 | 60,709 |
| Brudnick RichardDirector | – | $180,520 | 2 | 2025-05-29 | 16,457 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-01 | Peng KatieDirector | Saleplan | 2,988 | 53.56 | $160,037 | 36,759 | Form 4 |
| 2026-07-01 | Peng KatieDirector | Saleplan | 2,437 | 54.25 | $132,207 | 34,322 | Form 4 |
| 2026-07-01 | Peng KatieDirector | Saleplan | 21 | 54.96 | $1,154 | 34,301 | Form 4 |
| 2026-07-01 | Reed JoshuaDirector | Saleplan | 2,105 | 53.50 | $112,618 | 20,466 | Form 4 |
| 2026-07-01 | Reed JoshuaDirector | Saleplan | 948 | 54.28 | $51,457 | 19,518 | Form 4 |
| 2026-07-01 | Burow KristinaDirector | Saleplan | 2,105 | 53.49 | $112,596 | 115,605 | Form 4 |
| 2026-07-01 | Burow KristinaDirector | Saleplan | 948 | 54.28 | $51,457 | 114,657 | Form 4 |
| 2026-07-01 | Gilman MichaelDirector | Saleplan | 1,346 | 53.54 | $72,065 | 60,709 | Form 4 |
| 2026-07-01 | Gilman MichaelDirector | Saleplan | 1,155 | 54.23 | $62,636 | 59,554 | Form 4 |
| 2026-07-01 | Gilman MichaelDirector | Saleplan | 43 | 54.81 | $2,357 | 59,511 | Form 4 |
| 2026-07-01 | Flier Jeffrey S.Director | Saleplan | 1,568 | 53.53 | $83,935 | 29,341 | Form 4 |
| 2026-07-01 | Flier Jeffrey S.Director | Saleplan | 1,470 | 54.24 | $79,733 | 27,871 | Form 4 |
| 2026-07-01 | Flier Jeffrey S.Director | Saleplan | 15 | 54.88 | $823 | 27,856 | Form 4 |
| 2026-04-16 | Hallal DavidDirector, Chief Executive Officer | Sale | 30,615 | 49.57 | $1.52M | 1,639,034 | Form 4 |
| 2026-04-16 | Sinha VikasChief Financial Officer | Sale | 10,410 | 49.57 | $516,024 | 619,856 | Form 4 |
| 2026-04-16 | Vaishnaw AkshayDirector, President of R&D | Sale | 12,246 | 49.57 | $607,034 | 630,542 | Form 4 |
| 2026-04-16 | Woods KeithChief Operating Officer | Sale | 10,220 | 49.57 | $506,605 | 620,055 | Form 4 |
| 2026-02-23 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Saleplan | 7,427 | 46.94 | $348,623 | 99,502 | Form 4 |
| 2026-02-23 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Saleplan | 857 | 47.86 | $41,016 | 98,645 | Form 4 |
| 2026-02-23 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Saleplan | 200 | 48.48 | $9,696 | 98,445 | Form 4 |
| 2026-02-17 | Marantz Jing L.CHIEF MEDICAL OFFICER | Sale | 4,157 | 46.53 | $193,425 | 126,012 | Form 4 |
| 2026-02-17 | Ho JunlinGENERAL COUNSEL | Sale | 9,580 | 46.53 | $445,757 | 241,545 | Form 4 |
| 2026-02-17 | Parlavecchio CarynCHRO | Sale | 9,035 | 46.53 | $420,399 | 169,087 | Form 4 |
| 2026-02-17 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Sale | 7,989 | 46.53 | $371,728 | 106,929 | Form 4 |
| 2026-01-22 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Saleplan | 2,119 | 45.87 | $97,199 | 98,439 | Form 4 |
| 2026-01-22 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Saleplan | 12,779 | 46.85 | $598,696 | 85,660 | Form 4 |
| 2026-01-16 | Marantz Jing L.CHIEF MEDICAL OFFICER | Sale | 5,798 | 44.48 | $257,895 | 95,687 | Form 4 |
| 2026-01-16 | Ho JunlinGENERAL COUNSEL | Sale | 8,016 | 44.48 | $356,552 | 214,553 | Form 4 |
| 2026-01-16 | Parlavecchio CarynCHRO | Sale | 6,600 | 44.48 | $293,568 | 148,864 | Form 4 |
| 2026-01-16 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Sale | 8,406 | 44.48 | $373,899 | 100,558 | Form 4 |
| 2026-01-14 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Saleplan | 13,112 | 45.20 | $592,662 | 108,964 | Form 4 |
| 2026-01-13 | Hallal DavidDirector, Chief Executive Officer | Sale | 57,450 | 42.70 | $2.45M | 1,541,645 | Form 4 |
| 2026-01-13 | Vaishnaw AkshayDirector, President of R&D | Sale | 20,438 | 42.70 | $872,703 | 595,767 | Form 4 |
| 2026-01-13 | Woods KeithChief Operating Officer | Sale | 16,746 | 42.70 | $715,054 | 583,254 | Form 4 |
| 2026-01-13 | Sinha VikasChief Financial Officer | Sale | 16,755 | 42.70 | $715,438 | 583,245 | Form 4 |
| 2025-12-16 | Peng KatieDirector | Saleplan | 726 | 43.88 | $31,857 | 33,188 | Form 4 |
| 2025-12-16 | Peng KatieDirector | Saleplan | 280 | 44.63 | $12,496 | 32,908 | Form 4 |
| 2025-12-04 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Saleplan | 136,462 | 45.21 | $6.17M | 108,964 | Form 4 |
| 2025-10-07 | Akkaraju SrinivasDirector | Buyindirect | 12,796 | 39.31 | $503,011 | 513,235 | Form 4 |
| 2025-10-07 | Akkaraju SrinivasDirector | Buyindirect | 12,400 | 40.18 | $498,232 | 525,635 | Form 4 |
69 more
| 2025-10-07 | Akkaraju SrinivasDirector | Buyindirect | 4,403 | 40.97 | $180,391 | 530,038 | Form 4 |
| 2025-10-06 | Akkaraju SrinivasDirector | Buyindirect | 18,414 | 37.89 | $697,706 | 405,828 | Form 4 |
| 2025-10-06 | Akkaraju SrinivasDirector | Buyindirect | 80,863 | 38.68 | $3.13M | 486,691 | Form 4 |
| 2025-10-06 | Akkaraju SrinivasDirector | Buyindirect | 13,748 | 39.52 | $543,321 | 500,439 | Form 4 |
| 2025-10-03 | Akkaraju SrinivasDirector | Buyindirect | 11,011 | 35.61 | $392,102 | 11,011 | Form 4 |
| 2025-10-03 | Akkaraju SrinivasDirector | Buyindirect | 56,703 | 36.74 | $2.08M | 67,714 | Form 4 |
| 2025-10-03 | Akkaraju SrinivasDirector | Buyindirect | 319,700 | 37.42 | $11.96M | 387,414 | Form 4 |
| 2025-09-22 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Sale | 3,353 | 30.67 | $102,837 | 108,964 | Form 4 |
| 2025-09-16 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Sale | 3,178 | 33.52 | $106,527 | 112,317 | Form 4 |
| 2025-09-16 | Peng KatieDirector | Saleplan | 930 | 32.48 | $30,206 | 33,990 | Form 4 |
| 2025-09-16 | Peng KatieDirector | Saleplan | 76 | 33.20 | $2,523 | 33,914 | Form 4 |
| 2025-08-18 | Parlavecchio CarynCHRO | Sale | 2,178 | 31.17 | $67,888 | 155,464 | Form 4 |
| 2025-07-16 | Flier Jeffrey S.Director | Saleplanindirect | 11,136 | 40.02 | $445,663 | 0 | Form 4 |
| 2025-07-08 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Saleplan | 24,066 | 34.44 | $828,833 | 115,495 | Form 4 |
| 2025-06-23 | Flier Jeffrey S.Director | Saleplan | 17,550 | 32.16 | $564,408 | 26,836 | Form 4 |
| 2025-06-23 | Flier Jeffrey S.Director | Saleplan | 2,766 | 32.74 | $90,559 | 24,070 | Form 4 |
| 2025-06-23 | Flier Jeffrey S.Director | Saleplanindirect | 11,136 | 33.21 | $369,827 | 11,136 | Form 4 |
| 2025-06-16 | Ho JunlinGENERAL COUNSEL | Sale | 7,442 | 32.00 | $238,144 | 222,569 | Form 4 |
| 2025-06-16 | Parlavecchio CarynCHRO | Sale | 6,186 | 32.00 | $197,952 | 157,642 | Form 4 |
| 2025-06-16 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Sale | 3,668 | 32.00 | $117,376 | 139,561 | Form 4 |
| 2025-06-16 | Peng KatieDirector | Saleplan | 2,977 | 31.96 | $95,145 | 34,974 | Form 4 |
| 2025-06-16 | Peng KatieDirector | Saleplan | 54 | 32.53 | $1,757 | 34,920 | Form 4 |
| 2025-05-29 | Vaishnaw AkshayDirector, President of R&D | Saleplan | 5,130 | 29.63 | $152,002 | 617,825 | Form 4 |
| 2025-05-29 | Vaishnaw AkshayDirector, President of R&D | Saleplan | 1,620 | 30.01 | $48,616 | 616,205 | Form 4 |
| 2025-05-29 | Reed JoshuaDirector | Saleplan | 4,900 | 29.68 | $145,432 | 16,232 | Form 4 |
| 2025-05-29 | Reed JoshuaDirector | Saleplan | 500 | 30.04 | $15,020 | 15,732 | Form 4 |
| 2025-05-29 | Brudnick RichardDirector | Saleplan | 4,675 | 29.63 | $138,520 | 16,457 | Form 4 |
| 2025-05-29 | Brudnick RichardDirector | Saleplan | 1,400 | 30.00 | $42,000 | 15,057 | Form 4 |
| 2025-05-29 | Gilman MichaelDirector | Saleplan | 630 | 29.22 | $18,409 | 57,961 | Form 4 |
| 2025-05-29 | Gilman MichaelDirector | Saleplan | 2,745 | 29.83 | $81,883 | 55,216 | Form 4 |
| 2025-05-29 | Burow KristinaDirector | Saleplan | 1,000 | 29.24 | $29,240 | 25,471 | Form 4 |
| 2025-05-29 | Burow KristinaDirector | Saleplan | 4,400 | 29.83 | $131,252 | 21,071 | Form 4 |
| 2025-05-29 | Flier Jeffrey S.Director | Saleplan | 1,100 | 29.23 | $32,153 | 29,045 | Form 4 |
| 2025-05-29 | Flier Jeffrey S.Director | Saleplan | 4,975 | 29.84 | $148,454 | 24,070 | Form 4 |
| 2025-04-25 | Sacco TraceyChief Commercial Officer | Saleplan | 4,916 | 32.81 | $161,294 | 71,834 | Form 4 |
| 2025-04-25 | Sacco TraceyChief Commercial Officer | Saleplan | 84 | 33.49 | $2,813 | 71,750 | Form 4 |
| 2025-03-24 | Moore ErinInterim PFO and PAO | Saleplan | 13,564 | 33.12 | $449,240 | 82,609 | Form 4 |
| 2025-03-24 | Sacco TraceyChief Commercial Officer | Saleplan | 1,500 | 33.70 | $50,550 | 76,750 | Form 4 |
| 2025-03-24 | Sacco TraceyChief Commercial Officer | Saleplan | 5,000 | 32.89 | $164,450 | 71,750 | Form 4 |
| 2025-03-17 | Peng KatieDirector | Saleplan | 1,006 | 34.42 | $34,627 | 30,319 | Form 4 |
| 2025-03-10 | Myles Edward HCOO & CFO | Saleplan | 112,897 | 35.82 | $4.04M | 140,740 | Form 4 |
| 2025-03-10 | Myles Edward HCOO & CFO | Saleplan | 29,395 | 34.87 | $1.03M | 111,345 | Form 4 |
| 2025-02-19 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Saleplan | 39,967 | 37.20 | $1.49M | 139,627 | Form 4 |
| 2025-02-19 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Saleplan | 8,341 | 37.56 | $313,288 | 131,286 | Form 4 |
| 2025-02-19 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Saleplan | 20,202 | 37.74 | $762,423 | 111,084 | Form 4 |
| 2025-02-18 | Backstrom Jay T.Director, CHIEF EXECUTIVE OFFICER | Sale | 18,372 | 36.83 | $676,641 | 311,991 | Form 4 |
| 2025-02-18 | Ho JunlinGENERAL COUNSEL | Sale | 5,742 | 36.83 | $211,478 | 189,295 | Form 4 |
| 2025-02-18 | Myles Edward HCOO & CFO | Sale | 7,809 | 36.83 | $287,605 | 140,740 | Form 4 |
| 2025-02-18 | Parlavecchio CarynCHRO | Sale | 5,296 | 36.83 | $195,052 | 140,258 | Form 4 |
| 2025-02-18 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Saleplan | 4,135 | 36.83 | $152,292 | 131,286 | Form 4 |
| 2025-01-16 | Ho JunlinGENERAL COUNSEL | Sale | 9,039 | 44.20 | $399,524 | 195,037 | Form 4 |
| 2025-01-16 | Myles Edward HCOO & CFO | Sale | 12,539 | 44.20 | $554,224 | 148,549 | Form 4 |
| 2025-01-16 | Parlavecchio CarynCHRO | Sale | 6,434 | 44.20 | $284,383 | 145,554 | Form 4 |
| 2025-01-16 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Sale | 7,347 | 44.20 | $324,737 | 135,421 | Form 4 |
| 2025-01-16 | Sacco TraceyChief Commercial Officer | Sale | 3,890 | 44.20 | $171,938 | 45,395 | Form 4 |
| 2025-01-16 | Marantz Jing L.CHIEF MEDICAL OFFICER | Sale | 5,655 | 44.20 | $249,951 | 67,200 | Form 4 |
| 2025-01-16 | Backstrom Jay T.Director, CHIEF EXECUTIVE OFFICER | Sale | 22,308 | 44.20 | $986,014 | 330,363 | Form 4 |
| 2024-12-10 | Debbane Raymond10% ownerwith Invus Public Equities Advisors, LLC, Invus Public Equities, L.P., Siren, L.L.C., Invus Global Management, LLC | Sale | 1,600,000 | 41.65 | $66.64M | 9,250,005 | Form 4 |
| 2024-11-25 | Debbane Raymond10% ownerwith Invus Public Equities Advisors, LLC, Invus Public Equities, L.P., Siren, L.L.C., Invus Global Management, LLC | Sale | 208,272 | 37.63 | $7.84M | 11,051,166 | Form 4 |
| 2024-11-25 | Debbane Raymond10% ownerwith Invus Public Equities Advisors, LLC, Invus Public Equities, L.P., Siren, L.L.C., Invus Global Management, LLC | Sale | 43,887 | 38.43 | $1.69M | 11,007,279 | Form 4 |
| 2024-11-25 | Debbane Raymond10% ownerwith Invus Public Equities Advisors, LLC, Invus Public Equities, L.P., Siren, L.L.C., Invus Global Management, LLC | Sale | 126,442 | 39.51 | $5.00M | 10,880,837 | Form 4 |
| 2024-11-25 | Debbane Raymond10% ownerwith Invus Public Equities Advisors, LLC, Invus Public Equities, L.P., Siren, L.L.C., Invus Global Management, LLC | Sale | 30,683 | 40.14 | $1.23M | 10,850,154 | Form 4 |
| 2024-11-25 | Debbane Raymond10% ownerwith Invus Public Equities Advisors, LLC, Invus Public Equities, L.P., Siren, L.L.C., Invus Global Management, LLC | Sale | 149 | 40.98 | $6,106 | 10,850,005 | Form 4 |
| 2024-11-25 | Marantz Jing L.CHIEF MEDICAL OFFICER | Saleplan | 1,000 | 38.04 | $38,040 | 78,230 | Form 4 |
| 2024-11-25 | Marantz Jing L.CHIEF MEDICAL OFFICER | Saleplan | 2,100 | 39.25 | $82,425 | 76,130 | Form 4 |
| 2024-11-25 | Marantz Jing L.CHIEF MEDICAL OFFICER | Saleplan | 3,075 | 39.93 | $122,785 | 73,055 | Form 4 |
| 2024-11-25 | Marantz Jing L.CHIEF MEDICAL OFFICER | Saleplan | 200 | 40.72 | $8,144 | 72,855 | Form 4 |
| 2024-11-22 | Marantz Jing L.CHIEF MEDICAL OFFICER | Saleplan | 2,145 | 30.01 | $64,371 | 72,855 | Form 4 |
| 2024-11-11 | Marantz Jing L.CHIEF MEDICAL OFFICER | Saleplan | 2,105 | 30.00 | $63,150 | 72,855 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
37 × grant or award33 × option exercise5 × gift2 × option exercise
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-24 | Woods KeithChief Operating Officer | Gift G | −48,034 | – | 572,021 | Form 4 |
| 2026-09-21 | Hallal DavidDirector, Chief Executive Officer | Gift G | −36,652 | – | 1,602,382 | Form 4 |
| 2026-06-04 | Akkaraju SrinivasDirector | Grant or award A | +6,839 | – | 27,971 | Form 4 |
| 2026-06-04 | Peng KatieDirector | Grant or award A | +6,839 | – | 39,747 | Form 4 |
| 2026-06-04 | Gilman MichaelDirector | Grant or award A | +6,839 | – | 62,055 | Form 4 |
| 2026-06-04 | Burow KristinaDirector | Grant or award A | +6,839 | – | 117,710 | Form 4 |
| 2026-06-04 | Brudnick RichardDirector | Grant or award A | +6,839 | – | 21,896 | Form 4 |
| 2026-06-04 | Reed JoshuaDirector | Grant or award A | +6,839 | – | 22,571 | Form 4 |
| 2026-06-04 | Flier Jeffrey S.Director | Grant or award A | +6,839 | – | 30,909 | Form 4 |
| 2026-04-23 | Burow KristinaDirector | Option exercise M | +7,800 | 26.78 | 28,871 | Form 4 |
| 2026-04-23 | Burow KristinaDirector | Option exercise M | +28,000 | 4.75 | 56,871 | Form 4 |
| 2026-04-23 | Burow KristinaDirector | Option exercise M | +36,000 | 9.11 | 92,871 | Form 4 |
| 2026-04-23 | Burow KristinaDirector | Option exercise M | +18,000 | 8.36 | 110,871 | Form 4 |
| 2026-02-09 | Woods KeithChief Operating Officer | Grant or award A | +47,021 | – | 630,275 | Form 4 |
| 2026-02-09 | Hallal DavidDirector, Chief Executive Officer | Grant or award A | +128,004 | – | 1,669,649 | Form 4 |
| 2026-02-09 | Ho JunlinGeneral Counsel | Grant or award A | +36,572 | – | 251,125 | Form 4 |
| 2026-02-09 | Marantz Jing L.Chief Medical Officer | Grant or award A | +34,482 | – | 130,169 | Form 4 |
| 2026-02-09 | Parlavecchio CarynChief Human Resources Officer | Grant or award A | +29,258 | – | 178,122 | Form 4 |
| 2026-02-09 | Qatanani MoChief Scientific Officer | Grant or award A | +29,258 | – | 114,918 | Form 4 |
| 2026-02-09 | Sinha VikasChief Financial Officer | Grant or award A | +47,021 | – | 630,266 | Form 4 |
| 2026-02-09 | Vaishnaw AkshayDirector, President of R&D | Grant or award A | +47,021 | – | 642,788 | Form 4 |
| 2026-01-14 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Option exercise M | +1,407 | 18.08 | 110,371 | Form 4 |
| 2026-01-14 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Option exercise M | +321 | 7.62 | 110,692 | Form 4 |
| 2026-01-14 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Option exercise M | +2,813 | 10.00 | 113,505 | Form 4 |
| 2026-01-14 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Option exercise M | +5,893 | 15.75 | 119,398 | Form 4 |
| 2026-01-14 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Option exercise M | +2,678 | 35.15 | 122,076 | Form 4 |
| 2025-12-12 | Akkaraju SrinivasDirector | Option exercise X | +1,064,804 | 7.35 | 6,367,614 | Form 4 |
| 2025-12-11 | Debbane Raymond10% owner | Option exercise X | +1,575,008 | 7.35 | 10,825,013 | Form 4 |
| 2025-12-04 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Option exercise M | +65,625 | 26.05 | 174,589 | Form 4 |
| 2025-12-04 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Option exercise M | +21,093 | 18.08 | 195,682 | Form 4 |
| 2025-12-04 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Option exercise M | +5,607 | 4.86 | 201,289 | Form 4 |
| 2025-12-04 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Option exercise M | +1,281 | 7.62 | 202,570 | Form 4 |
| 2025-12-04 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Option exercise M | +11,250 | 10.00 | 213,820 | Form 4 |
| 2025-12-04 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Option exercise M | +23,571 | 15.75 | 237,391 | Form 4 |
| 2025-12-04 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Option exercise M | +8,035 | 35.15 | 245,426 | Form 4 |
| 2025-10-08 | Hallal DavidDirector, Chief Executive Officer | Gift G | −205,000 | – | 1,599,095 | Form 4 |
| 2025-06-23 | Flier Jeffrey S.Director | Option exercise M | +20,316 | 21.62 | 44,386 | Form 4 |
| 2025-06-09 | Ho JunlinGENERAL COUNSEL | Grant or award A | +8,571 | – | 230,011 | Form 4 |
| 2025-05-22 | Flier Jeffrey S.Director | Grant or award A | +7,632 | – | 30,145 | Form 4 |
| 2025-05-22 | Gilman MichaelDirector | Grant or award A | +7,632 | – | 58,591 | Form 4 |
| 2025-05-22 | Peng KatieDirector | Grant or award A | +7,632 | – | 37,951 | Form 4 |
| 2025-05-22 | Akkaraju SrinivasDirector | Grant or award A | +7,632 | – | 21,132 | Form 4 |
| 2025-05-22 | Burow KristinaDirector | Grant or award A | +7,632 | – | 26,471 | Form 4 |
| 2025-05-22 | Reed JoshuaDirector | Grant or award A | +7,632 | – | 21,132 | Form 4 |
| 2025-05-22 | Brudnick RichardDirector | Grant or award A | +7,632 | – | 21,132 | Form 4 |
| 2025-04-27 | Sinha VikasChief Financial Officer | Grant or award A | +100,000 | – | 100,000 | Form 4 |
| 2025-04-27 | Sinha VikasChief Financial Officer | Grant or award A | +500,000 | – | 600,000 | Form 4 |
| 2025-04-27 | Hallal DavidDirector, CEO | Grant or award A | +250,000 | – | 554,095 | Form 4 |
| 2025-04-27 | Hallal DavidDirector, CEO | Grant or award A | +1,250,000 | – | 1,804,095 | Form 4 |
| 2025-04-27 | Vaishnaw AkshayDirector, President of R&D | Grant or award A | +100,000 | – | 122,955 | Form 4 |
| 2025-04-27 | Vaishnaw AkshayDirector, President of R&D | Grant or award A | +500,000 | – | 622,955 | Form 4 |
| 2025-04-27 | Woods KeithChief Operating Officer | Grant or award A | +100,000 | – | 100,000 | Form 4 |
| 2025-04-27 | Woods KeithChief Operating Officer | Grant or award A | +500,000 | – | 600,000 | Form 4 |
| 2025-04-25 | Sacco TraceyChief Commercial Officer | Option exercise M | +5,000 | 10.00 | 76,250 | Form 4 |
| 2025-03-24 | Moore ErinInterim PFO and PAO | Option exercise M | +5,000 | 23.86 | 87,609 | Form 4 |
| 2025-03-24 | Moore ErinInterim PFO and PAO | Option exercise M | +8,564 | 13.52 | 96,173 | Form 4 |
| 2025-03-24 | Sacco TraceyChief Commercial Officer | Option exercise M | +5,000 | 10.00 | 78,250 | Form 4 |
| 2025-03-10 | Myles Edward HCOO & CFO | Option exercise M | +21,690 | 13.83 | 162,430 | Form 4 |
| 2025-03-10 | Myles Edward HCOO & CFO | Option exercise M | +43,122 | 18.08 | 205,552 | Form 4 |
| 2025-03-10 | Myles Edward HCOO & CFO | Option exercise M | +24,915 | 4.86 | 230,467 | Form 4 |
| 2025-03-10 | Myles Edward HCOO & CFO | Option exercise M | +5,313 | 10.00 | 235,780 | Form 4 |
| 2025-03-10 | Myles Edward HCOO & CFO | Option exercise M | +17,857 | 15.75 | 253,637 | Form 4 |
| 2025-03-10 | Sacco TraceyChief Commercial Officer | Grant or award A | +27,855 | – | 73,250 | Form 4 |
| 2025-03-10 | Ho JunlinGENERAL COUNSEL | Grant or award A | +32,145 | – | 221,440 | Form 4 |
| 2025-03-10 | Backstrom Jay T.Director, CHIEF EXECUTIVE OFFICER | Grant or award A | +113,570 | – | 425,561 | Form 4 |
| 2025-03-10 | Marantz Jing L.CHIEF MEDICAL OFFICER | Grant or award A | +34,285 | – | 101,485 | Form 4 |
| 2025-03-10 | Parlavecchio CarynCHRO | Grant or award A | +23,570 | – | 163,828 | Form 4 |
| 2025-03-10 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Grant or award A | +32,145 | – | 143,229 | Form 4 |
| 2025-02-19 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Option exercise M | +16,818 | 4.86 | 148,104 | Form 4 |
| 2025-02-19 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Option exercise M | +2,562 | 7.62 | 150,666 | Form 4 |
| 2025-02-19 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Option exercise M | +11,250 | 10.00 | 161,916 | Form 4 |
| 2025-02-19 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Option exercise M | +17,678 | 15.75 | 179,594 | Form 4 |
| 2024-11-25 | Marantz Jing L.CHIEF MEDICAL OFFICER | Option exercise M | +6,375 | 8.59 | 79,230 | Form 4 |
| 2024-11-22 | Marantz Jing L.CHIEF MEDICAL OFFICER | Option exercise M | +2,145 | 8.59 | 75,000 | Form 4 |
| 2024-11-12 | Gilman MichaelDirector | Gift G | −37,459 | – | 0 | Form 4 |
| 2024-11-12 | Gilman MichaelDirector | Gift G | +37,459 | – | 50,959 | Form 4 |
| 2024-11-11 | Marantz Jing L.CHIEF MEDICAL OFFICER | Option exercise M | +2,105 | 8.59 | 74,960 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.